Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
In-vitro Colorectal Cancer Screening Tests Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The in-vitro colorectal cancer screening tests market size has demonstrated strong expansion in recent years. It is anticipated to increase from $1.3 billion in 2025 to $1.4 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. The market’s past growth can be attributed to several factors including rising colorectal cancer incidence rates, the proliferation of population screening initiatives, enhanced public awareness concerning early cancer detection, the availability of laboratory-based diagnostic infrastructure, and improvements in biomarker identification.
The in-vitro colorectal cancer screening tests market size is projected to experience substantial expansion in the coming years, with expectations to reach $1.82 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.8%. This anticipated growth during the forecast period is primarily attributable to factors such as the greater embrace of personalized screening methods, a surge in demand for convenient at-home diagnostic options, the broader rollout of preventive healthcare programs, the expanding application of AI in interpreting results, and a heightened emphasis on economical cancer screening solutions. Key developments anticipated during this timeframe include the wider acceptance of non-invasive screening tests, an increase in multi-target stool DNA testing applications, the growing incorporation of blood-based biomarker assays, the proliferation of home-based sample collection kits, and a stronger focus on identifying cancer early in individuals without symptoms.
Get A Free Sample Report With In-Depth Market Insights:
In-vitro Colorectal Cancer Screening Tests Market Growth Catalysts And Demand Drivers
The escalating incidence of colorectal cancer is projected to drive the growth of the in vitro colorectal cancer screening tests market in the future. Colorectal cancer is a type of malignancy that originates in the colon or rectum, often evolving from precancerous polyps. The increasing prevalence of colorectal cancer is attributed to unhealthy lifestyle habits, given that poor diet, lack of exercise, and obesity elevate the risk of polyp formation and subsequent cancer development. In-vitro colorectal cancer screening tests assist in colorectal cancer diagnosis by providing non-invasive methods for detecting early signs of the disease. These tests improve screening accuracy through advanced biomarker detection, thereby enhancing early intervention and patient outcomes. For instance, in February 2025, according to the American Cancer Society, a US-based nonprofit organization, the estimated number of new colorectal cancer cases was 154,270, an increase from 152,810 cases in 2024. Thus, the rising prevalence of colorectal cancer is propelling the expansion of the in vitro colorectal cancer screening tests market.
In-vitro Colorectal Cancer Screening Tests Market Segment Landscape: Which Areas Lead Development?
The in-vitro colorectal cancer screening tests market covered in this report is segmented –
1) By Test Type: Fecal Occult Blood Test, Stool Deoxyribonucleic Acid Test, Blood Biomarker Test, Other Test Types
2) By Imaging Type: In-vitro Confirmatory Diagnostics, Laboratory-Based Molecular Testing, Companion Diagnostic Testing, Genetic And Epigenetic Testing, Biomarker Validation Testing, Risk Stratification Assays
3) By Application: Screening, Diagnosis, Monitoring, Risk Assessment, Post-Treatment Surveillance
4) By End User: Hospitals, Diagnostic Laboratories, Outpatient Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test
2) By Stool Deoxyribonucleic Acid Test: Single Target Stool Deoxyribonucleic Acid Test, Multi Target Stool Deoxyribonucleic Acid Test
3) By Blood Biomarker Test: Methylated Septin 9 Deoxyribonucleic Acid Test, Circulating Tumor Deoxyribonucleic Acid Test, Protein Biomarker Based Blood Test
4) By Other Test Types: Urine Based Biomarker Test, Serum Based Biomarker Test, Breath Based Volatile Organic Compound Test
In-vitro Colorectal Cancer Screening Tests Market Trends Shaping Long-Term Demand
Leading companies in the in vitro colorectal cancer screening tests market are concentrating on developing advanced diagnostic solutions, such as multi-target stool DNA tests. Their goal is to enhance early detection accuracy, improve patient convenience, and reduce colorectal cancer mortality rates. Multi-target stool DNA tests are innovative screening tools designed to analyze stool samples for genetic and biochemical markers associated with colorectal cancer and precancerous lesions. For example, in March 2025, Exact Sciences Corp., a US-based molecular diagnostics company, launched Cologuard Plus, an enhanced at-home colorectal cancer screening test for average-risk adults aged 45 and older. This test integrates advanced biomarker technology, providing higher sensitivity and specificity than its predecessor. It utilizes a refined algorithm to detect DNA mutations and hemoglobin biomarkers, thereby improving the detection of both colorectal cancer and advanced adenomas. The Cologuard Plus test offers a non-invasive and convenient screening option that eliminates the need for bowel preparation or dietary restrictions, subsequently increasing patient adherence to recommended screening guidelines.
In-vitro Colorectal Cancer Screening Tests Market Industry Leaders And Competitive Landscape
Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV, Hologic Inc., Danaher Corporation, Agilent Technologies Inc.
View The Full In-vitro Colorectal Cancer Screening Tests Market Report:
In-vitro Colorectal Cancer Screening Tests Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the in-vitro colorectal cancer screening tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
